Skip to content
Axcess News – Lifestyle
Author:
Moderna, Inc.
Moderna to Present Revaccination Data for Its Investigational Seasonal Influenza Vaccine and for mRESVIA at ESCMID 2026
April 7, 2026
Moderna Resolves Global Patent Litigation with Arbutus/Genevant
March 7, 2026
European Medicines Agency’s Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Marketing Authorization of mCOMBRIAX, Moderna’s mRNA Combination Vaccine Against Influenza and COVID-19
March 6, 2026
Moderna to Present at Upcoming Conferences in March 2026
March 5, 2026
Moderna Announces the U.S. Food and Drug Administration will Initiate the Review of Its Investigational Seasonal Influenza Vaccine Submission
March 4, 2026
←
Previous Page
1
2
3